Pixantrone Named-Patient Program Initiated in Europe
SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009.
"Our focus for the first half of 2009 was to initiate and complete the NDA submission for pixantrone while we implemented final steps in our cost cutting efforts and raised much needed operating capital on the least dilutive terms possible -- all while cleaning up the Company's capital structure," said James A. Bianco, M.D., CEO of CTI. "We are pleased with our results as reflected in our first quarter financials. We have cut our net operating losses attributable to common shareholders by 76%, raised gross proceeds of $44.3 million in 2009 and eliminated all of our outstanding preferred stock, while staying on track to complete the NDA submission for pixantrone in June 2009."
Total net operating expenses decreased $21.8 million, or 77%, to $6.6 million for the quarter ended March 31, 2009 compared to $28.4 million for the same period in 2008 as a result of a $10.2 million one-time gain on the sale CTI's investment in the Zevalin joint venture coupled with a decrease in research and development expenses. Excluding the one-time gain, total net operating expenses decreased 41% over the same period last year. Research and development expenses decreased 7.9 million, or 50%, to $8.0 million for the current quarter compared to $15.9 million for the same period in 2008 as the result of cost reduction initiatives and expenses related to our clinical trial programs. Net loss attributable to common shareholders decreased $41.5 million, or 76%, to $13.1 million ($0.05 per share) for the quarter ended March 31, 2009, compared to $54.6 million ($7.68 per share) for the comparable period in 2008. The reduction in net loss per share is primarily due to an increase in the number of shares outstanding, reduction of expenses and gain on sale of CTI's investment in the Zevalin joint venture.
CTI had approximately $0.7 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of March 31, 2009. In addition, on April 3, 2009, CTI received $6.5 million in gross proceeds from Spectrum associated with the sale of its interest in the Zevalin joint venture and expects to receive up to an additional $3.5 million upon the completion of Spectrum's payment obligations to CTI. In April 2009 CTI received $20.0 million in gross proceeds upon the sale of its Series 1 Preferred Stock and an additional $3.8 million upon the exercise of the associated common stock warrants in May 2009.
Conference Call Information
On Thursday, May 7, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss CTI's 2009 first quarter achievements and financial results.
Conference Call Numbers Thursday, May 7 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-888-561-1799 (US Participants) 1-480-629-9867 (International) Call-back numbers for post-listening available at 11:30 a.m. Eastern: 1-800-406-7325 (US Participants) 1-303-590-3030 (International) Passcode: 4066143
Live audio webcast at www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the possibility that we may not receive all of the additional amount owed to us by Spectrum, our ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in our filings with the Securities and Exchange Commission including, without limitation, our most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, we do not intend to update or alter our forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 F: 206.272.4434 E: email@example.com www.celltherapeutics.com/media.htm Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: firstname.lastname@example.org www.celltherapeutics.com/investors.htm
Three Months Ended March 31, --------- 2009 2008 ---- ---- Revenues: Product sales $- $3,374 License and contract revenue 20 20 -- -- Total revenues 20 3,394 -- ----- Operating expenses, net: Cost of product sold - 890 Research and development 7,956 15,855 Selling, general and administrative 8,874 11,210 Amortization of purchased intangibles - 397 Gain on sale of Zevalin (10,244) - ------- --- Total operating expenses, net 6,586 28,352 ----- ------ Loss from operations (6,566) (24,958) Other income (expense): Investment and other income, net 34 260 Interest expense (1,617) (1,985) Amortization of debt discount and issuance costs (4,851) (10,944) Foreign exchange gain (loss) 41 (2,237) Make-whole interest expense (6,345) (7,781) Gain on derivative liabilities, net 5,622 11,744 Loss on exchange of convertible notes - (2,295) Equity loss from investment in joint venture (1,204) - Settlement expense (170) - ---- --- Net loss before noncontrolling interest (15,056) (38,196) Noncontrolling interest 89 32 -- -- Net loss attributable to CTI (14,967) (38,164) Gain on restructuring of preferred stock 2,116 - Preferred stock dividends (23) (242) Deemed dividends on conversion of preferred stock (250) (16,198) ---- ------- Net loss attributable to CTI common shareholders $(13,124) $(54,604) ======== ======== Basic and diluted net loss per common share $(0.05) $(7.68) ====== ====== Shares used in calculation of basic and diluted net loss per common share (1) 285,525 7,107 ======= ===== Balance Sheet Data: (amounts in thousands) March 31, December 31, 2009 2008 ---- ---- (unaudited) Cash and cash equivalents and securities available-for-sale $748 $10,671 Restricted cash - 6,640 Working capital (22,776) (14,141) Total assets 42,933 64,243 Convertible debt 119,030 142,373 Accumulated deficit (1,325,444) (1,312,320) Total deficit (115,984) (132,061) (1) Amounts reflect a one-for-ten reverse stock split of our common stock effective August 31, 2008.
|SOURCE Cell Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved